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ASCs for radiation-induced salivary hypofunction and 
xerostomia and found it safe and significantly imp 
roved salivary gland functions and patient-reported 
outcomes. 
 
SP-0336  Reducing normal tissue damage by sparing of 
stem cells using protons 
P. Van Luijk1 
1University of Groningen- University Medical Center 
Groningen, Radiation Oncology, Groningen, The 
Netherlands  
 
Abstract text 
Radiotherapy plays an important role in the treatment of 
many forms of cancer. However, dose to normal tissue 
frequently leads to damage, toxicity and reduction of 
quality of life of the patient.  
Xerostomia is a frequently-observed side-effect of the 
treatment of head-and-neck tumors, associated with 
irradiation of the parotid gland. Recently it has been 
shown that the response of the parotid gland critically 
depends on dose to its major ducts, containing most of its 
stem cells. The observation that sparing of a relatively 
small substructure of an organ is important to preserve its 
function after radiotherapy opened new opportunities for 
reducing toxicity. In addition, recent pre-clinical work 
suggests that tissue-specific stem cells are particularly 
sensitive to low doses of radiation.  
Interestingly, these findings coincides with an increasing 
availability of proton therapy world-wide. The precision of 
protons provides unique opportunities to specifically spare 
such substructures. In addition they offer more 
opportunities to limit the large volumes receiving low 
doses, as typically observed in Intensity Modulated 
Radiotherapy. 
In conclusion, based on the unique properties of protons 
and available information from radiobiology, proton 
therapy may offer unique opportunities to reduce toxicity 
of radiotherapy. 
 
SP-0337  Mechanisms of radiotherapy-induced  
neurocognitive decline 
L. Barazzuol1,2 
1UMCG, Department Of Radiation Oncology, Groningen, 
The Netherlands; 2umcg, Department Of Biomedical 
Sciences Of Cells And Systems, Groningen, The 
Netherlands  
 
Abstract text 
Radiotherapy is an essential part of the treatment of 
paediatric and adult primary brain tumours. Although 
long-term survival rates are increasing, 50 to 90% of the 
surviving patients develop neurological dysfunction 
leading to a reduced quality of life. Symptoms include a 
progressive impairment in memory, executive function 
and processing speed. In particular, children and young 
adults suffer from significant loss of intelligence quotient, 
with an average IQ decline of over 2 points per year. The 
pathogenesis of radiation-induced neurocognitive 
dysfunction is not well understood and consequently no 
effective treatment or prevention strategy exist. My 
laboratory, by using a combination of methodologies, 
including cerebral organoids and in vivo models, aims to 
reduce radiotherapy-induced neurocognitive dysfunction. 
Radiotherapy mainly works by damaging the DNA. To date, 
the link between DNA damage and neuropathology is not 
fully understood. Yet it is widely accepted that diminished 
protein homeostasis can cause neurodegeneration in aging 
and protein-misfolding diseases (such as Alzheimer’s and 
Parkinson’s disease).  
Our recent data provide the first evidence that radiation-
induced DNA damage leads to loss of protein homeostasis. 
Using different model systems, from primary neuronal and 
glial cells, human ES/iPS-derived cortical organoids to 
mouse and rat models, we have shown elevated protein 
aggregation levels after DNA damage caused either 
directly by radiation or indirectly by impairment of the 
DNA damage response. This imbalance in protein 
homeostasis can be reduced by modulating the protein 
quality control capacity. In this presentation, new 
molecular targets for the future development of 
interventions will be presented. 
 
SP-0338  Neurocognition and brain irradiation 
S. Deprez1 
1KUleuven, Imaging and Pathology, Leuven, Belgium  
 
Abstract text 
Whole brain irradiation (WBRT) is an important treatment 
modality in the management of brain 
metastases.  Additionally, WBRT in the form of 
prophylactic cranial irradiation (PCI) is often used to 
reduce the incidence of  brain metastatases  in for 
example small-cell lung cancer.  Although effective in 
cancer control, WBRT has important neurotoxic side 
effects.  Fifty percent or more of patients who survive 
6 months or longer after WBRT report cognitive 
dysfunction. Functional deficits including impairments in 
memory, attention and executive functioning can have a 
serious impact on quality of life. Mechanisms of radiation-
induced cognitive impairment are still poorly understood. 
The pathophysiology of brain injury after RT is 
multifactorial and complex. Possible mechanisms include 
CNS-irradiation triggered neuroinflammation, decreased 
hippocampal neurogenesis and vascular injury. Both early 
stage (< 6m after RT) and late delayed (>6m) brain injury 
can contribute to the observed cognitive dysfunction. 
Various pharmacologic and non-pharmacologic strategies 
to prevent or alleviate these toxicities are being 
investigated. In this talk an overview will be given of 
current knowledge in the field of neurocognition and brain 
irradiation, possible mechanisms  of radiation-induced 
cognitive impairment and strategies for preservation being 
investigated. 
 
 
Symposium: Radiotherapy in the era of the Silver 
Tsunami  
 
 
SP-0339  Cancer epidemiology in Europe with focus on 
indications for RT 
J. Overgaard1 
1Aarhus University Hospital, Dept. of Clinical 
Experimental Oncology, Aarhus, Denmark 
 
Abstract not received  
   
SP-0340  Does normal tissue in elderly patients have 
different sensitivity and tolerance and do tumors 
require different treatment?  
C. Herskind1,  
1Universitätsmedizin Mannheim- Medical Faculty Mannhe
im- Heidelberg University, 
Department of Radiation Oncology, Mannheim, Germany  
 
Abstract text 
In clinical practice patients are often considered elderly 
from the age of 65-70 years. However, in the developed 
world with high life expectancy, healthy persons of this 
age have an expected remaining life span of 15-20 years, 
and even persons with an attained age of 75-80 years are 
expected to live for another 8-12 years or longer. 
Therefore, long-term survival and quality of life is as 
important for cancer patients in this age group as in 
younger patients. It is a commonly made assumption that 
elderly patient show poorer tolerance and may not be 
eligible for radiotherapy protocols used in curative 
treatment of patients below this age. However, there is 
little high-level evidence to support this view. The 
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presentation will summarize the biological changes 
associated with increasing age and will emphasize the 
large individual variation observed. Clinical studies of the 
sensitivity and tolerance of normal tissue in elderly 
patients will be reviewed and the role of co-morbidities 
will be discussed. Furthermore, the available data on 
survival outcome of standard treatment protocols for 
different tumour entities will be considered. The bulk of 
the current evidence seriously questions the common 
practice of excluding cancer patients from study protocols 
solely on the basis of their chronological age 
 
SP-0341  Influence of age and comorbidity on outcome 
and compliance to RT 
C.R. Boeje1, J. Overgaard2 
1Aalborg University Hospital, Dept of Oncology, Aalborg, 
Denmark; 2Aarhus University Hospital, Dept. of Clinical 
Experimental Oncology, Aarhus, Denmark  
 
Abstract text 
Head and neck cancer (HNC) patients are often long term 
users of tobacco and/or alcohol. Besides the carcinogenic 
effect of these substances they also lead to other chronic 
diseases and thus contributes to a high prevalence of 
comorbidities among HNC patients. Due to demographic 
changes the general population becomes older and 
consequently more HNC patients may suffer from 
comorbidity. Severe comorbidity may impact on prognosis 
for HNC patients and may impact treatment decision, 
compliance and subsequent outcome. 
This talk will focus on comorbidity and age in HNC patients 
and the impact on survival. Data will be presented from 
different studies including large population based study 
from the DAHANCA group. These studies show that 
comorbidity is common among HNC patients and is a 
negative prognostic factor for overall survival. 
Comorbidity also have a negative impact on cancer 
specific survival, while age does not. Therefore, critical 
assessment of comorbidity can significantly improve the 
decision-making proces for clinicians and may influence 
and improve patient outcome. 
 
SP-0342  From geriatric assessment in radiation 
oncology to interventions: experience from the PIVOG 
trial 
D. Vordermark1 
1Martin Luther University Halle-Wittenberg, Dept. of 
Radiation Oncology, Halle/Saale, Germany  
 
Abstract text 
The demographic development in Europe e. g. in Germany 
leads to increasing need of adapted care concepts for 
elderly cancer patients. General principles (e. g. "go-go, 
slow-go, no-go" for very fit, quite fit and unfit elderly 
patients, respectively) are difficult to translate into 
clinical treatment recommendations for individual 
patients.Maintaining quality of life is highly important for 
elderly cancer patients. Its measurement, however, has 
only become possible recently with established of normal 
reference values for elderly age groups (e. g. for the 
EORTC QLQ-C30 questionnaire) and the validation of an 
elderly- specific instrument (QLQ-ELD 14; Wheelwright et 
al., Br J Cancer 2013).  
Using these tools, we could show in an observational study 
of n=50 very elderly (>80 years old) cancer patients 
undergoing radiotherapy, that general and elderly-specific 
quality of life remained stable from beginning to end of 
radiotherapy, but deteriorated in several domains, 
including physical function, role function and family 
support by 6 months after treatment (Kaufmann et al., 
Support Care Cancer 2015). A possible explanation was the 
good access to supportive treatment during radiotherapy, 
but lack thereof after treatment. 
 We interpreted this as a need to develop an intervention 
to stabilize quality of life of elderly cancer patients after 
the end end of treatment and developed a complex 
intervention containing (a) a clinically feasible 
comprehensive geriatric assessemtn (CGA) before the 
start of cancer treatment and (b) regular telephone 
contact with an oncology nurse during the first six months 
after treatment to counsel patients on the management of 
symptoms and provide additional ressources of care.  
This intervention was pilot tested in n=100 elderly patients 
over 70 years with at least one comorbidity and / or one 
functional impairment in the PIVOG trial (Patient-
centered Interdisciplinary Care Concept for Geriatric 
Oncology Patients; Schmidt et al., J Geriat Oncol 2017). 
The geriatric assessment was feasible and took on 
average one hour. The nurse-led telephone contact was 
well accepted (used by 79% of patients, mean 7.8 calls per 
patient, mean duration 14 minutes).  In the primary 
endpoint, global quality of life at 6-month follow-up, 
mean scores were stabilized compared to baseline. 
Clinically relevant improvement and deterioration were 
seen in 35% and 28% of patients, respectively, no change 
in 37%. Details on the experience with specific elements 
of the geriatric assessment and development in subscales 
of quality of life will be presented. Ongoing work is 
focussed on developing the complex intervention for 
evaluation in a randomized trial, on physical exercise to 
improve or stabilize physical function in elderly cancer 
patients and on the implementation of electronic patient-
reported outcome measurement in geriatric oncology 
using the CHES platform. 
 
 
Debate: Which is the best brachytherapy technique to 
deliver partial breast irradiation? Pitfalls, results and 
current recommendations  
 
 
SP-0343  Postoperative multicatheter brachytherapy 
J. Hannoun-Levi1 
1Centre Antoine Lacassagne, Radiation Therapy, Nice, 
France  
 
Abstract text 
Whatever the breast brachytherapy indication (boost, 
APBI for primary or APBrI for salvage irradiation), breast 
brachytherapy can be performed intra or post-operatively. 
We listed the different point which can be positively or 
negatively impacted if the implant is performed intra or 
postoperatively.Regarding breast brachytherapy 
applicators,in case of intra-operative implant, both 
multicatheter and balloon devices (single or multilumen) 
can be used, while in case of postoperative implant 
multicatheter brachy is the only one possible 
technique.For patient comfort regarding toanesthesia, in 
case of intra-op implant, the patient is under general 
anesthesia which is more comfortable compare to a local 
one in a postoperative implant.Regarding to “Vectors in 
place” duration, in case of intra-operative implant, before 
starting the irradiation, it is warranted to obtain the full 
postoperative pathological report which takes between 5 
to 8 days plus 4 to 5 more days for the treatment itself for 
a total duration ranged between 10 to 15 days (patient 
discomfort, risk of local infection and/or pain).However, 
in case of post-operative implant, the “Vectors in place” 
duration is reduced to the treatment duration itself 
plus/minus the delay between the implant and the first 
day of irradiation.For brachytherapist comfort regarding 
to anesthesia in case of intra-op implant, surgeon and 
brachytherapist can work together, with a full visibility of 
the tumor bed and the clip position. No pressure due to 
potential patient pain. In case of post-operative implant, 
it is sometimes difficult to perform the implant when the 
patient is not totally relaxed, obliging the brachytherapist 
to do the implant in a shorter time (potential stress). In 
terms of organization, in case of intra-operative implant, 
the brachytherapist must be available at the time of the 
